NVS vs TXG
Novartis AG vs 10x Genomics, Inc. — AI-powered side-by-side comparison
VS
TXG
10x Genomics, Inc.
53
Watch
| Metric | NVS | TXG |
|---|
| AI Score |
75
|
53
|
| Price |
$154.64
|
$58.48
|
| P/E Ratio |
23.55×
|
-99.12×
|
| ROE |
30.5%
|
-5.5%
|
| Revenue Growth YoY |
—
|
—
|
| Gross Margin |
74.3%
|
70.0%
|
| Debt / Equity |
1.18×
|
0.10×
|
| Dividend Yield |
2.9%
|
0.0%
|
| RSI (14) |
57.7
|
79.3
|
| Beta |
0.462
|
2.039
|
| Expected Upside |
+2.4%
|
—
|
AI Committee View
Current Innellis committee reasoning for NVS versus TXG.
NVS leads by 22 points.
NVS scores 75/100 (Buy) versus TXG at 53/100 (Watch).
NVS Committee View
100% agreement
5 analysts
The primary driver is quarter-over-quarter growth rate is accelerating, not just positive. The main limiting factor is 2 existing position pair(s) are highly correlated already. The committee is constructive but not yet at full conviction.
Bull Case
- Quarter-over-quarter growth rate is ACCELERATING, not just positive — Growth
- Price structure making higher highs and higher lows — Technical
- Trend and market structure agree -- coherent bullish picture — Technical
Bear Case
- MACD histogram negative -- bearish momentum — Technical
TXG Committee View
50% agreement
6 analysts
The committee is genuinely divided. Macro Analyst sees a compelling case — vix regime is low -- calm backdrop supports risk-taking. Growth Analyst remains cautious — revenue declining -4.3% yoy -- this is not a growth story right now. This disagreement is itself the signal — the setup is not clean in either direction.
Bull Case
- Price structure making higher highs and higher lows — Technical
- MACD histogram positive -- bullish momentum — Technical
- Trend and market structure agree -- coherent bullish picture — Technical
Bear Case
- ROE of only -9.3% -- cheap may mean cheap for a reason — Value
- Revenue declining -4.3% YoY -- this is not a growth story right now — Growth
- RSI at 79 is in overbought territory — Technical